The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Raf-Induced Proliferation or Cell Cycle Arrest Is Determined by the Level of Raf Activity with Arrest Mediated by p21Cip1
Open accessAbstract
The Raf family of protein kinases display differences in their abilities to promote the entry of quiescent NIH 3T3 cells into the S phase of the cell cycle. Although conditional activation of deltaA-Raf:ER promoted cell cycle progression, activation of deltaRaf-1:ER and deltaB-Raf:ER elicited a G1 arrest that was not overcome by exogenously added growth factors. Activation of all three deltaRaf:ER kinases led to elevated expression of cyclin D1 and cyclin E and reduced expression of p27Kip1. However, activation of deltaB-Raf:ER and deltaRaf-1:ER induced the expression of p21Cip1, whereas activation of deltaA-Raf:ER did not. A catalytically potentiated form of deltaA-Raf:ER, generated by point mutation, strongly induced p21Cip1 expression and elicited cell cycle arrest similarly to deltaB-Raf:ER and deltaRaf-1:ER. These data suggested that the strength and duration of signaling by Raf kinases might influence the biological outcome of activation of this pathway. By titration of deltaB-Raf:ER activity we demonstrated that low levels of Raf activity led to activation of cyclin D1-cdk4 and cyclin E-cdk2 complexes and to cell cycle progression whereas higher Raf activity elicited cell cycle arrest correlating with p21Cip1 induction and inhibition of cyclin-cdk activity. Using green fluorescent protein-tagged forms of deltaRaf-1:ER in primary mouse embryo fibroblasts (MEFs) we demonstrated that p21Cip1 was induced by Raf in a p53-independent manner, leading to cell cycle arrest. By contrast, activation of Raf in p21Cip1(-/-) MEFs led to a robust mitogenic response that was similar to that observed in response to platelet-derived growth factor. These data indicate that, depending on the level of kinase activity, Raf can elicit either cell cycle progression or cell cycle arrest in mouse fibroblasts. The ability of Raf to elicit cell cycle arrest is strongly associated with its ability to induce the expression of the cyclin-dependent kinase inhibitor p21Cip1 in a manner that bears analogy to alpha-factor arrest in Saccharomyces cerevisiae. These data are consistent with a role for Raf kinases in both proliferation and differentiation of mammalian cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibodies, a laboratory manual
(1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90130-3 · Cited by 12,366
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Marshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906
Morgan, D. O. (1995) · Nature · doi:10.1038/374131a0 · Cited by 3,284
Inhibitors of mammalian G1 cyclin-dependent kinases.
Sherr, C. J., & Roberts, J. M. (1995) · Genes & Development · doi:10.1101/gad.9.10.1149 · Cited by 3,243
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804 · cited 1×
“However, it is clear from the multistage nature of human cancer and from cell culture experiments involving cooperating oncogenes that expression of activated Ras is insufficient for oncogenic transformation (36, 41, 42).”
Background
Cited by
Calcium's Role in Mechanotransduction during Muscle Development
Benavides Damm, T., & Egli, M. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000356667 · Cited by 14,502
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
p21 in cancer: Intricate networks and multiple activities
Abbas, T., & Dutta, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2657 · Cited by 2,712
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Chang, F., Lehmann, B., Terrian, D. M., Milella, M., Tafuri, A., et al. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.10.001 · Cited by 2,284
The essence of senescence: Figure 1.
Kuilman, T., Michaloglou, C., Mooi, W. J., & Peeper, D. S. (2010) · Genes & Development · doi:10.1101/gad.1971610 · Cited by 2,038
Fridman, J. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1207116 · Cited by 1,401
ERK and cell death: mechanisms of ERK-induced cell death--apoptosis, autophagy and senescence
Cagnol, S., & Chambard, J. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07366.x · Cited by 1,290
The RAF proteins take centre stage
Wellbrock, C., Karasarides, M., & Marais, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1498 · Cited by 1,228
BrafV600E cooperates with Pten loss to induce metastatic melanoma
Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189
Self-citationThe MAPK signalling pathways and colorectal cancer
Fang, J. Y., & Richardson, B. C. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70168-6 · Cited by 1,185
Chang, F., Lee, J. T., Navolanic, P. M., Steelman, L. S., Shelton, J. G., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2402824 · Cited by 1,176
Stott, F. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,167
Meloche, S., & Pouysségur, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210414 · Cited by 1,091
Chien, Y., Scuoppo, C., Wang, X., Fang, X., Balgley, B., Bolden, J. E., Premsrirut, P., Luo, W., Chicas, A., Lee, C. S., et al. (2011) · Genes & Development · doi:10.1101/gad.17276711 · Cited by 1,046
Lin, A. W., Barradas, M., Stone, J. C., van Aelst, L., Serrano, M., & Lowe, S. W. (1998) · Genes & Development · doi:10.1101/gad.12.19.3008 · Cited by 945
Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP
Yeung, K., Seitz, T., Li, S., Janosch, P., McFerran, B., Kaiser, C., Fee, F., Katsanakis, K. D., Rose, D. W., Mischak, H., et al. (1999) · Nature · doi:10.1038/43686 · Cited by 893
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Holderfield, M., Deuker, M. M., McCormick, F., & McMahon, M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3760 · Cited by 833
Self-citationSenescence of human fibroblasts induced by oncogenic Raf
Zhu, J., Woods, D., McMahon, M., & Bishop, J. M. (1998) · Genes & Development · doi:10.1101/gad.12.19.2997 · Cited by 826
Self-citationGarnett, M. J., & Marais, R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.022 · Cited by 799
Bar-Sagi, D., & Hall, A. (2000) · Cell · doi:10.1016/s0092-8674(00)00115-x · Cited by 779
Nanoscale surfaces for the long-term maintenance of mesenchymal stem cell phenotype and multipotency
McMurray, R. J., Gadegaard, N., Tsimbouri, P. M., Burgess, K. V., McNamara, L. E., Tare, R., Murawski, K., Kingham, E., Oreffo, R. O. C., & Dalby, M. J. (2011) · Nature Materials · doi:10.1038/nmat3058 · Cited by 779
ERK implication in cell cycle regulation
Chambard, J.-C., Lefloch, R., Pouysségur, J., & Lenormand, P. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.11.010 · Cited by 750
The Raf/MEK/ERK pathway: new concepts of activation
Peyssonnaux, C., & Eychène, A. (2001) · Biology of the Cell · doi:10.1016/s0248-4900(01)01125-x · Cited by 735
Ca2+ signalling checkpoints in cancer: remodelling Ca2+ for cancer cell proliferation and survival
Roderick, H. L., & Cook, S. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2374 · Cited by 731
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., Dummer, R., McMahon, M., & Stuart, D. D. (2013) · Nature · doi:10.1038/nature11814 · Cited by 730
Self-citationChang, F., Steelman, L. S., Lee, J. T., Shelton, J. G., Navolanic, P. M., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2402945 · Cited by 725
Mapk signal specificity: The right place at the right time
Murphy, L. O., & Blenis, J. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.03.009 · Cited by 707
c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms
Wisdom, R. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.188 · Cited by 685
Transcriptional Regulation of the p21(WAF1/CIP1)Gene
Gartel, A. L., & Tyner, A. L. (1999) · Experimental Cell Research · doi:10.1006/excr.1998.4319 · Cited by 664
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance
McCubrey, J. A., Steelman, L. S., Abrams, S. L., Lee, J. T., Chang, F., Bertrand, F. E., Navolanic, P. M., Terrian, D. M., Franklin, R. A., D’Assoro, A. B., et al. (2006) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2006.01.004 · Cited by 664
Quantification of Short Term Signaling by the Epidermal Growth Factor Receptor
Kholodenko, B. N., Demin, O. V., Moehren, G., & Hoek, J. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.42.30169 · Cited by 618
Ley, R., Balmanno, K., Hadfield, K., Weston, C., & Cook, S. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301010200 · Cited by 608
Negative feedback regulation of the ERK1/2 MAPK pathway
Lake, D., Corrêa, S. A. L., & Müller, J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2297-8 · Cited by 565
Modulation of mammalian life span by the short isoform of p53
Maier, B., Gluba, W., Bernier, B., Turner, T., Mohammad, K., Guise, T., Sutherland, A., Thorner, M., & Scrable, H. (2004) · Genes & Development · doi:10.1101/gad.1162404 · Cited by 586
Dual‐specificity MAP kinase phosphatases (MKPs): Shaping the outcome of MAP kinase signalling
Caunt, C. J., & Keyse, S. M. (2013) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08716.x · Cited by 535
Tumour cell survival signalling by the ERK1/2 pathway
Balmanno, K., & Cook, S. J. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.148 · Cited by 484
Nosaka, T. (1999) · The EMBO Journal · doi:10.1093/emboj/18.17.4754 · Cited by 491
Dankort, D., Filenova, E., Collado, M., Serrano, M., Jones, K., & McMahon, M. (2007) · Genes & Development · doi:10.1101/gad.1516407 · Cited by 481
Self-citationRegulation of MAPKs by growth factors and receptor tyrosine kinases
Katz, M., Amit, I., & Yarden, Y. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.01.002 · Cited by 467
Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1
Olson, M. F., Paterson, H. F., & Marshall, C. J. (1998) · Nature · doi:10.1038/28425 · Cited by 464
High-Intensity Raf Signal Causes Cell Cycle Arrest Mediated by p21 Cip1
Sewing, A., Wiseman, B., Lloyd, A. C., & Land, H. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.9.5588 · Cited by 462
The ERK Cascade: A Prototype of MAPK Signaling
Rubinfeld, H., & Seger, R. (2005) · Molecular Biotechnology · doi:10.1385/mb:31:2:151 · Cited by 460
Integrating the MAP kinase signal into the G1 phase cell cycle machinery
Roovers, K., & Assoian, R. K. (2000) · BioEssays · doi:10.1002/1521-1878(200009)22:9<818::aid-bies7>3.0.co;2-6 · Cited by 458
Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation
Mason, C. S. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2137 · Cited by 457
Raf proteins and cancer: B-Raf is identified as a mutational target
Mercer, K. E., & Pritchard, C. A. (2003) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(03)00016-7 · Cited by 457
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
Sharma, S. V., & Settleman, J. (2007) · Genes & Development · doi:10.1101/gad.1609907 · Cited by 441
Agger, K., Cloos, P. A. C., Rudkjær, L., Williams, K., Andersen, G., Christensen, J., & Helin, K. (2009) · Genes & Development · doi:10.1101/gad.510809 · Cited by 427
“This version of BRAF is fused to the ligand-binding domain of the estrogen receptor (ER), and the activity of this protein is rapidly induced by 4-hydroxytamoxifen (OHT) (Woods et al. 1997).”
BackgroundERK Activation Mediates Cell Cycle Arrest and Apoptosis after DNA Damage Independently of p53
Tang, D., Wu, D., Hirao, A., Lahti, J. M., Liu, L., Mazza, B., Kidd, V. J., Mak, T. W., & Ingram, A. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111598200 · Cited by 422
Multiple Ras Effector Pathways Contribute to G1Cell Cycle Progression
Gille, H., & Downward, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.22033 · Cited by 409
Modulation of the Ras/Raf/MEK/ERK pathway by Ca2+, and Calmodulin
Agell, N., Bachs, O., Rocamora, N., & Villalonga, P. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(02)00007-4 · Cited by 398
Sahai, E. (2001) · The EMBO Journal · doi:10.1093/emboj/20.4.755 · Cited by 384
Tumor suppressors and oncogenes in cellular senescence
Bringold, F., & Serrano, M. (2000) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00083-8 · Cited by 379
The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review
Wang, L. G., Liu, X. M., Kreis, W., & Budman, D. R. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050989 · Cited by 373
Amati, B. (1998) · Frontiers in Bioscience · doi:10.2741/a239 · Cited by 367
Opposing Effects of Ras on p53
Ries, S., Biederer, C., Woods, D., Shifman, O., Shirasawa, S., Sasazuki, T., McMahon, M., Oren, M., & McCormick, F. (2000) · Cell · doi:10.1016/s0092-8674(00)00123-9 · Cited by 357
Self-citationRAS and RHO GTPases in G1-phase cell-cycle regulation
Coleman, M. L., Marshall, C. J., & Olson, M. F. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1365 · Cited by 355
Schroeder, J. A., Thompson, M. C., Gardner, M. M., & Gendler, S. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011248200 · Cited by 346
Rodriguez-Viciana, P., Sabatier, C., & McCormick, F. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.11.4943-4954.2004 · Cited by 327
Ebisuya, M., Kondoh, K., & Nishida, E. (2005) · Journal of Cell Science · doi:10.1242/jcs.02505 · Cited by 331
Growth Factors and Mitogen-Activated Protein Kinases
Force, T., & Bonventre, J. V. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.152 · Cited by 327
Dent, P., Reardon, D. B., Park, J. S., Bowers, G., Logsdon, C., Valerie, K., & Schmidt-Ullrich, R. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.8.2493 · Cited by 326
A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?
Smalley, K. S. M. (2003) · International Journal of Cancer · doi:10.1002/ijc.10978 · Cited by 325
Signal Transduction and Cellular Radiation Responses
Schmidt-Ullrich, R. K., Dent, P., Grant, S., Mikkelsen, R. B., & Valerie, K. (2000) · Radiation Research · doi:10.1667/0033-7587(2000)153[0245:stacrr]2.0.co;2 · Cited by 316
Ras and Rho regulation of the cell cycle and oncogenesis
Pruitt, K., & Der, C. J. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00528-6 · Cited by 311
Dumaz, N., Hayward, R., Martin, J., Ogilvie, L., Hedley, D., Curtin, J. A., Bastian, B. C., Springer, C., & Marais, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4227 · Cited by 304
Kurata, H., Lee, H. J., O'Garra, A., & Arai, N. (1999) · Immunity · doi:10.1016/s1074-7613(00)80142-9 · Cited by 299
Raf kinases in cancer–roles and therapeutic opportunities
Maurer, G., Tarkowski, B., & Baccarini, M. (2011) · Oncogene · doi:10.1038/onc.2011.160 · Cited by 292
Regulation of Cell Cycle Progression by Growth Factor-Induced Cell Signaling
Wang, Z. (2021) · Cells · doi:10.3390/cells10123327 · Cited by 287
Lehmann, K., Janda, E., Pierreux, C. E., Rytömaa, M., Schulze, A., McMahon, M., Hill, C. S., Beug, H., & Downward, J. (2000) · Genes & Development · doi:10.1101/gad.181700 · Cited by 287
Self-citationControl of the eukaryotic cell cycle by MAP kinase signaling pathways
Wilkinson, M. G., & Millar, J. B. A. (2000) · The FASEB Journal · doi:10.1096/fj.00-0102rev · Cited by 280
Phospholipase D Signaling Pathways and Phosphatidic Acid as Therapeutic Targets in Cancer
Bruntz, R. C., Lindsley, C. W., & Brown, H. A. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.009217 · Cited by 276
Reactive oxygen species-dependent signaling regulates cancer
Weinberg, F., & Chandel, N. S. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0099-y · Cited by 275
Lopez, T., & Hanahan, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00055-7 · Cited by 268
Yamamoto, T., Ebisuya, M., Ashida, F., Okamoto, K., Yonehara, S., & Nishida, E. (2006) · Current Biology · doi:10.1016/j.cub.2006.04.044 · Cited by 259
Elucidating Distinct Roles for NF1 in Melanomagenesis
Maertens, O., Johnson, B., Hollstein, P., Frederick, D. T., Cooper, Z. A., Messiaen, L., Bronson, R. T., McMahon, M., Granter, S., Flaherty, K., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0313 · Cited by 258
Self-citationBlagosklonny, M. V. (2012) · Aging · doi:10.18632/aging.100443 · Cited by 251
“Because strong growth-promoting (mitogenic) signals induce cell cycle arrest [48-54], strong mitogenic signaling causes both conditions of senescence: arrest and mTOR/growth signal (Figure 2A).”
BackgroundDigitalis-Induced Signaling by Na+/K+-ATPase in Human Breast Cancer Cells
Kometiani, P., Liu, L., & Askari, A. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.007302 · Cited by 208
Pantoja, C., & Serrano, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202880 · Cited by 201
Ras/Mitogen-Activated Protein Kinase Signaling Activates Ets-1 and Ets-2 by CBP/p300 Recruitment
Foulds, C. E., Nelson, M. L., Blaszczak, A. G., & Graves, B. J. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10954-10964.2004 · Cited by 190
Parry, D., Mahony, D., Wills, K., & Lees, E. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1775 · Cited by 174
Self-citationDow, L. E., Elsum, I. A., King, C. L., Kinross, K. M., Richardson, H. E., & Humbert, P. O. (2008) · Oncogene · doi:10.1038/onc.2008.219 · Cited by 171
Cell senescence and hypermitogenic arrest
Blagosklonny, M. V. (2003) · The EMBO Reports · doi:10.1038/sj.embor.embor806 · Cited by 156
Integrin-mediated signalling through the MAP-kinase pathway
Yee, K. L., Weaver, V. M., & Hammer, D. A. (2008) · IET Systems Biology · doi:10.1049/iet-syb:20060058 · Cited by 117
de Keizer, P. L. J., Packer, L. M., Szypowska, A. A., Riedl-Polderman, P. E., van den Broek, N. J. F., de Bruin, A., Dansen, T. B., Marais, R., Brenkman, A. B., & Burgering, B. M. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1563 · Cited by 94
Hansen, S. H., Zegers, M. M. P., Woodrow, M., Rodriguez-Viciana, P., Chardin, P., Mostov, K. E., & McMahon, M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.24.9364-9375.2000 · Cited by 85
Self-citationRas biochemistry and farnesyl transferase inhibitors. A literature survey
Crul, M., de Klerk, G. J., Beijnen, J. H., & Schellens, J. H. (2001) · Anti-Cancer Drugs · doi:10.1097/00001813-200103000-00001 · Cited by 75
Ras protein abundance correlates with Ras isoform mutation patterns in cancer
Hood, F. E., Sahraoui, Y. M., Jenkins, R. E., & Prior, I. A. (2023) · Oncogene · doi:10.1038/s41388-023-02638-1 · Cited by 56
Ehrhardt, G. R. A., Leslie, K. B., Lee, F., Wieler, J. S., & Schrader, J. W. (1999) · Blood · doi:10.1182/blood.v94.7.2433.419k31_2433_2444 · Cited by 54
Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells
Amin, A. D., Rajan, S. S., Groysman, M. J., Pongtornpipat, P., & schatz, J. H. (2015) · Biomarkers in Cancer · doi:10.4137/bic.s29326 · Cited by 25
Vaishnavi, A., Scherzer, M. T., Kinsey, C. G., Parkman, G. L., Truong, A., Ghazi, P., Schuman, S., Battistone, B., Garrido-Laguna, I., & McMahon, M. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107994 · Cited by 23
Self-citationERK1/2 and p38 cooperate to delay progression through G1 by promoting cyclin D1 protein turnover
Densham, R. M., Todd, D. E., Balmanno, K., & Cook, S. J. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2008.07.005 · Cited by 22
Metadata
- Authors
- Woods, D., Parry, D., Cherwinski, H., Bosch, E., Lees, E., & McMahon, M.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1997-09-01
- Volume
- 17
- Issue
- 9
- Pages
- 5598-5611
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2136222819
- Cited by
- 639
- References
- 104
- FWCI
- 16.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.